# Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

> **NCT00126594** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 80 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Recurrent Renal Cell Carcinoma
- Stage IV Renal Cell Cancer

## Interventions

- **DRUG:** Sorafenib Tosylate
- **BIOLOGICAL:** Recombinant Interferon Alfa-2b
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT00126594
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2016-09-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00126594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00126594, "Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00126594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*